Thank you, Mr. Chair.
Thanks to the witnesses for being here today.
This isn't really a good look for the PMPRB in general. I imagine both of you probably joined the PMPRB—you, Mr. Clark, through the executive director role and you, Mr. Herder, through the board role—in a way, to make drug pricing better in this country. It's obviously spiralled to this point where you're here testifying before a health committee, as some of your former colleagues have.
Mr. Clark, you've been there at the PMPRB for quite a while. Where did this all start going down this path? Where did this begin that led you here today?